The Korean Society for Neuro-Oncology (KSNO) Guideline for Adult Diffuse Midline Glioma: Version 2021.1

Hong In Yoon1, Chan Woo Wee2, Young Zoon Kim3, Youngbeom Seo4, Jung Ho Im5, Yun-Sik Dho6, Kyung Hwan Kim7, Je Beom Hong8, Jae-Sung Park9, Seo Hee Choi10, Young Il Kim18, Ho Sung Kim14, Jin Mo Cho15, Wan-So Yoon16, Se Hoon Lee17, Young Il Kim18, Ho-Shin Gwak27, Myung-Hoon Han26, Se-Hoon Lee23, Jong Hee Chang24, Do Hoon Lim25, Chul-Kee Park11*, Youn Soo Lee26*, Ho-Shin Gwak27*; KSNO Guideline Working Group

Background There have been no guidelines for the management of adult patients with diffuse midline glioma (DMG), H3K27M-mutant in Korea since the 2016 revised WHO classification newly defined this disease entity. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, had begun preparing guidelines for DMG since 2019.

Methods The Working Group was composed of 27 multidisciplinary medical experts in Korea. References were identified through searches of PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL using specific and sensitive keywords as well as combinations of keywords. As ‘diffuse midline glioma’ was recently defined, and there was no international guideline, trials and guidelines of ‘diffuse intrinsic pontine glioma’ or ‘brain stem glioma’ were thoroughly reviewed first.

Results The core contents are as follows. The DMG can be diagnosed when all of the following three criteria are satisfied: the presence of the H3K27M mutation, midline location, and infiltrating feature. Without identification of H3K27M mutation by diagnostic biopsy, DMG cannot be diagnosed. For the primary treatment, maximal safe resection should be considered for tumors when feasible. Radiotherapy is the primary option for tumors in case the total resection is not possible. A total dose of 54 Gy to 60 Gy with conventional fractionation prescribed at 1–2 cm plus gross tumor volume is recommended. Although no chemotherapy has proven to be effective in DMG, concurrent chemoradiotherapy (+ maintenance chemotherapy) with temozolomide following WHO grade IV glioblastoma’s protocol is recommended.

Conclusion The detection of H3K27M mutation is the most important diagnostic criteria for DMG. Combination of surgery (if amenable to surgery), radiotherapy, and chemotherapy based on comprehensive multidisciplinary discussion can be considered as the treatment options for DMG.

Key Words Korean Society for Neuro-Oncology; Guideline; Diffuse midline glioma; Practice.
INTRODUCTION

'Diffuse midline glioma (DMG), H3K27M-mutant' is a newly established disease entity according to the 2016 revised version of the World Health Organization (WHO) classification of brain tumors [1]. H3K27M-mutant DMGs are high-grade gliomas (WHO grade IV) associated with local infiltration and a poor prognosis of an average survival time of less than one year [2]. The pons is the most common location of H3K27M-mutant DMG, however, they can also occur in the thalamus, spinal cord, and other midline locations in patients of all DMGs [3]. Importantly, H3K27M-mutant DMG is a pathologic diagnosis and is not synonymous with the clinical and radiologic entity of diffuse intrinsic pontine glioma (DIPG). DMG is a part of disease that was previously classified as 'DIPG' or 'brain stem glioma'. Approximately 80% of biopsied DIPGs harbor mutations at position K27 in one of several histone-encoding genes [4-6].

Despite the dismal prognosis of DMG, there are few randomized controlled clinical trials to establish the evidence-based standard treatment protocol. In general, surgery, radiotherapy, and chemotherapy can be considered as treatment options for DMG. If it is feasible, maximal safe resection can be considered as an initial treatment of choice. However, no superior treatment modalities including radiotherapy, chemotherapy, and/or surgery, have been recommended alone or in combination to others. There are no unified (inter)national guidelines of radio- and chemotherapy for DMG, which resulted in a heterogeneous application of treatments.

A practical guideline for the management of patients with central nervous system (CNS) tumors in Korea has been limited. Therefore, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society for CNS tumors, began to prepare guidelines for various types of brain tumors from February 2018. In 2019, a new Guideline Working Group chapter began to develop the practical guidelines for the management of DMG in Korea. The main purpose of KSNO guidelines for DMG is to 1) provide an opportunity to share relevant medical knowledge and experiences among experts through the development of treatment guidelines, 2) provide practical standard treatment information to medical staffs, 3) help determining the optimal treatment strategies for DMG through multidisciplinary approaches, and 4) prolong patient's life, improve quality of life, and ultimately contribute to the improvement of national health.

KSNO GUIDELINE WORKING GROUP

A new chapter of Working Group was appointed by the KSNO in 2019 to develop a clinical guideline for management of patients with brain tumor. These guidelines should be optimized considering the unique medical circumstance in Korea. The KSNO Guideline Working Group was composed of 27 medical experts in Korea, including 15 neurosurgeons, 6 radiation oncologists, 1 medical oncologist, 2 neuroradiologists, 2 pathologists, and 1 neurologist.

References were identified by searching PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL databases using specific and sensitive keywords as well as combinations of keywords. After 'diffuse midline glioma, H3K27M-mutant' was proposed as a new diagnostic entity in 2016, all retrospective and prospective clinical studies of this disease were reviewed. As there was no international guideline for management of DMG yet, the guidelines for the treatment of 'DIPG' or 'brain stem glioma' were also reviewed to develop this new guideline. If available, existing guidelines from national multidisciplinary neuro-oncological societies such as the National Comprehensive Cancer Network (NCCN) and European Association of Neuro-Oncology (EANO) were also collected. The language was limited to English and Korean. The publication year was not limited, but the papers published after 2016 were weighted more because DMG is a newly established disease entity since 2016. The selection of search terms and selection of suitable papers were conducted by reflecting the opinions of the members in charge. After reviewing the papers, a total of 51 papers were selected as references for this guideline.

Scientific evidence was evaluated and graded according to the following categories: high level evidence (obtained from multiple populations and derived from randomized clinical trials or meta-analysis or systemic review), and low level evidence (obtained from limited population and derived from non-randomized studies, including observational studies, cohort studies, and case-control studies).

To establish the recommendation levels, the following criteria were used. Level I (strong recommendation) required a high level evidence and uniform agreement among panels. Level II (weak recommendation) required a high level evidence but not uniform agreement among panels or low level evidence but uniform agreement among panels. Level III (no consensus; individual decision) required a low level evidence but not uniform agreement among panels. Level IV (not recommended) required contents being not beneficial or harmful.

DIAGNOSIS OF DIFFUSE MIDLINE GLIOMA

DMG is a rare type of glial tumor that occurs in the CNS. Previously, it referred to as 'DIPG'. More recently, it was known that some DIPGs with a specific mutation (H3K27M mutation) show characteristically dismal prognosis. Therefore, the
2016 revised WHO classification redefined this type of tumors as ‘diffuse midline glioma, H3K27M-mutant’, a new diagnostic entity based on its unique genetic signature [1]. Characteristically, 1) it is located in the midline of the brain (brain stem, spinal cord, cerebellum, thalamus, etc.), 2) shows a diffuse growth pattern, and 3) shows K27M mutation in H3F3A or HIST1H3B/C (H3K27M mutation) [7-9]. Because surgical resection is often difficult due to the delicate location of the tumor [10,11], proper imaging and biopsy are required for accurate diagnosis of DMG [12,13]. However, in some tumors, the location is often not suitable to perform a biopsy [10,11]. According to the previous European survey for health care professionals treating DIPG patients, only 13.5% of the respondents said to do biopsy all of their patients, while 41.9% of the respondents said to do biopsy their patients infrequently [14]. Characteristic radiologic findings shown only in DMG have not yet been clearly defined, and studies involving adult patients are further lacking. In general, when diagnosing by imaging findings without confirming the presence of H3K27M mutation, the presence of ‘extensive invasion’ in the midline structures of the CNS is an important finding. However, as these radiologic features are not shown in all cases, and histologic confirmation is more critical, sufficient discussion should be preceded when physicians diagnose this disease entity radiologically.

In summary, DMG can be diagnosed when all of the following three criteria are satisfied: 1) the presence of the H3K27M (H3F3A or HIST1H3B/C mutation), 2) midline location (thalamus, brain stem, spinal cord, etc.), and 3) infiltrating (diffuse) feature (Level I). Since the confirmation of H3K27M mutation is the most important diagnostic criteria for DMG rather than clinical and imaging features, tumor biopsy should be considered first (Level I) and immunostaining for the histone H3K27M mutation should be performed to detect the H3K27M mutation (Level I) [15]. Instead, detection of EGFR hotspot mutation or EZH2 overexpression can be used to diagnosis DMGs [16].

If histopathological feature of diffusely infiltrative growth in glioma at midline location and H3K27M mutation are detected, physicians can diagnose DMG (Level I). Even if H3K27M mutation is detected, physicians cannot diagnose DMG if the tumor is not located at the midline location (Level II). If the diagnostic biopsy is not possible or H3K27M mutation is not identified, the tumor cannot be diagnosed as DMG even if both location (midline) and infiltrating feature are satisfied. In this case, it is advisable to follow the treatment guidelines of other types of glioma in WHO classification (Level I) (Fig. 1, Table 1).

![Fig. 1. Diagnosis algorithm for diffuse midline glioma (DMG). To diagnose DMGs, detection of H3K27M mutation, the location of tumor (midline location), and infiltrating feature are essential (①+②+③). In other words, physicians are not recommended to diagnose DMG if the tumor is not located at the midline location (②), even if H3K27M mutation is detected (①). Also, if the diagnostic biopsy is not possible or H3K27M mutation is not identified (④), the tumor cannot be diagnosed as DMG even if both location (midline) (②) and infiltrating feature (③) are satisfied.](image-url)

### Table 1. Guideline for diagnosis of diffuse midline glioma

| Question 1. How should diffuse midline glioma be diagnosed? | Recommendation level |
|-------------------------------------------------------------|---------------------|
| 1-1. Diffuse midline glioma can be diagnosed when the following three criteria are satisfied: | Level I |
| ① Presence of the H3K27M (H3F3A or HIST1H3B/C) mutation | |
| ② Midline location (thalamus, brain stem, spinal cord, etc.) | |
| ③ Infiltrating (diffuse) feature (histopathologically) | |
| 1-2. To detect the H3K27M mutation, immunostaining for the histone H3K27M mutation should be performed. | Level I |
| 1-3. Even if H3K27M mutation is detected (①), physicians cannot diagnose diffuse midline glioma if the tumor is not located at the midline location (②). | Level II |
| 1-4. If the diagnostic biopsy is not possible or H3K27M mutation is not identified, the tumor cannot be diagnosed as diffuse midline glioma even if both ② and ③ are satisfied. In this case, it is advisable to follow the treatment guidelines of other types of glioma in WHO classification. | Level I |
**PRINCIPLES OF MANAGEMENT OF DIFFUSE MIDLINE GLIOMAS**

### Decision for primary treatment

Customarily, management of DMG have followed the standards of care for gliomas of the same WHO grade [17,18]. Combinations of surgery, radiotherapy, and chemotherapy can be considered as the treatment options for DMG [14,15,19]. For tumors that can be surgically resected safely, maximal safe resection should be considered first (Level II). The goal of surgery is to obtain tissue for genetic diagnosis and to reduce the tumor burden without harming neurological status of the patient [15,18,20]. However, the brainstem, thalamus, and spinal cord are neurologically critical structures and surgical procedures in these areas can cause serious irreversible deficits. Thus, management strategies including the scope and purpose of the surgery must be carefully determined through multidisciplinary discussion (Level II). Even if maximal safe resection is not feasible, biopsy of the tumor should be essentially confirmed to confirm the presence of H3K27M mutation for the diagnosis of DMG (Level II).

In addition to the surgical resection, radiotherapy and chemotherapy can also be added for the management of DMG [10,14,15,17,19]. Radiotherapy is the primary treatment option when the complete surgical resection is not feasible which is in the majority of cases (Level II). Concurrent chemotherapy using temozolomide can be considered when performing radiotherapy (Level II). Sequential chemotherapy after radiotherapy can also be performed in some cases. However, there has been no chemotherapy regimen which demonstrated meaningful benefit in DMG [21-23]. There is also a lack of reports that concurrent chemotherapy is superior to radiotherapy followed by chemotherapy, radiotherapy alone, or chemotherapy alone. Given these limitations, each plan should be tailored to each patient. A multidisciplinary discussion among experts including neuro-oncologists, neuroradiologists, radiation oncologists, and neurosurgeons, is important to determine the best treatment plan. At any time during the course of treatment, it is necessary to actively apply symptom-controlling drugs or procedures such as steroids or ventriculoperitoneal shunt when necessary (Level I) (Table 2).

### Radiotherapy

To determine the dose scheme of radiotherapy, it would be reasonable to follow the radiotherapy policy of DIPG, as the relevant papers for DMG are still lacking. Radiotherapy has been regarded as an important treatment option for brainstem glioma. In current situation, similar doses and fields can be recommended when performing radiotherapy in DMG. A total dose of 54 Gy to 60 Gy with conventional fractionation (1.8–2.0 Gy daily given five days per week) is recommended (Level II) [24]. Total dose of radiation should be determined by radiation oncologists. The dose-constraint of the brainstem should always be kept (Level II). Dose escalation is not recommended (Level II). The radiotherapy field can be defined as 1–2 cm plus gross tumor volume (GTV) (Level II) [25]. GTV includes not only contrast-enhancing lesions but also hyperintense lesions seen on T2-weighted, FLAIR images (Level II). For radiotherapy techniques, three-dimensional conformal radiation therapy using X-rays, intensity-modulated radiation therapy, and proton therapy [26] can be considered for radiotherapy techniques (Level II).

Despite multiple trials of dose escalation, hypofractionated radiotherapy [27-35], hypofractionated radiotherapy [36-40], and radiosensitization, none of these modulations have been proven more effective than the conventional radiotherapy. Patients with severe symptoms may require urgent initiation of radiotherapy. Due to the poor prognosis in patients with DIPG, hypofractionated radiation therapy has been evaluated to minimize the time spent in treatment. In a randomized trial of 71 children with newly diagnosed DIPG, a regimen of thirteen 3.0 Gy fractions was well tolerated, and median overall survival approached that of radiation therapy given over six weeks (7.8 versus 9.5 months) [36,41]. Based on this result, depending on

| Question 2. What is the primary treatment for diffuse midline glioma? | Recommendation level |
|---|---|
| 2-1. Surgery, radiotherapy, and chemotherapy can be considered as the treatment options for diffuse midline glioma. The scope of surgery and treatment policy for each patient should be determined through multidisciplinary discussion. | Level II |
| 2-2. For tumors that can be surgically resected safely, maximal safe resection should be considered first. | Level II |
| 2-3. Even if maximal safe resection is impossible considering the tumor location, possibility of tumor biopsy to confirm the presence of H3K27M mutation should be checked to diagnose diffuse midline glioma. | Level II |
| 2-4. Radiotherapy is the primary treatment option for tumors in which total surgical resection is not possible, or only partial resection is performed. | Level II |
| 2-5. Concurrent chemotherapy should be considered when performing radiotherapy. | Level II |
| 2-6. When a tumor causes neurological or systemic symptoms, it is necessary to actively apply symptom-controlling drugs. | Level I |
the patient’s condition and tumor location, the corresponding dose with hypo-fractionation can also be prescribed instead of 54–60 Gy with conventional fractionation in DMG (Level III).

Fractionated re-irradiation may be considered at the time of progression to temporarily extend palliation, although increased toxicities may result from this approach [42,43]. In a small prospective dose-escalation study of DMG, the lowest dose level (24 Gy in 12 fractions) was well tolerated and achieved imaging, clinical, and/or quality-of-life improvement in most patients; in all 12 patients, progression-free and overall survival from the start of re-irradiation were 4.5 and 5.8 months, respectively [44]. Also, re-irradiation may be considered to control symptoms and improve the survival outcomes in well-selected patients with persistent disease progression [42,45-47]. For the re-irradiation dose, 20–40 Gy with conventional fractionation can be recommended based on recent studies (Level III). Depending on the patient’s condition, corresponding dose with hypo-fractionation radiotherapy (≤3 Gy per fraction) can also be prescribed (Table 3).

### Table 3. Guideline for radiotherapy of patients with diffuse midline glioma

| Question 3. How should radiotherapy be performed in diffuse midline glioma? | Recommendation level |
|---|---|
| 3-1. A total dose of 54 Gy to 60 Gy with conventional fractionation (1.8–2.0 Gy daily given five days per week) is recommended; | Level II |
| i) Dose escalation is not recommended. | Level II |
| ii) Total dose of radiation should be determined by radiation oncologists. The dose-constraint of the brain stem should always be kept. | Level II |
| 3-2. Depending on the patient’s condition and tumor location, the corresponding dose with hypo-fractionation can also be prescribed instead of 54–60 Gy with conventional fractionation. | Level III |
| 3-3. The radiotherapy field can be defined as 1–2 cm plus gross tumor volume (GTV). GTV includes not only contrast-enhancing lesions but also hyperintense lesions seen on T2-weighted, FLAIR images. | Level II |
| 3-4. Three-dimensional conformal radiation therapy using X-rays, intensity-modulated radiation therapy, and proton therapy can be considered for radiotherapy techniques. | Level II |
| 3-5. Re-irradiation may be considered to control symptoms and improve the survival outcomes in some patients with persistent disease progression. For the re-irradiation dose, 20–40 Gy with conventional fractionation can be prescribed. | Level III |

### Table 4. Guideline for chemotherapy of patients with diffuse midline glioma

| Question 4. How should chemotherapy be performed in diffuse midline glioma? | Recommendation level |
|---|---|
| 4-1. Concurrent chemoradiotherapy (+ maintenance chemotherapy) can be considered a primary treatment or adjuvant treatment after surgery. | Level II |
| 4-2. As a chemotherapy regimen, temozolomide can be used during- and post-radiotherapy following WHO grade IV glioblastoma’s Stupp regimen protocol. | Level II |
| 4-3. When concurrent chemoradiotherapy is unsuitable considering the patient’s condition, radiotherapy alone is recommended. | Level II |
| 4-4. If the disease progresses after radiotherapy, maintenance chemotherapy with temozolomide can be applied. | Level III |
| 4-5. The single agent or combination therapy of chemotherapeutic agents other than temozolomide can be tried only after sufficient multidisciplinary discussion. | Level III |

---

**Chemotherapy**

No chemotherapy has been proven to be effective in DMG or DIPG. Numerous treatment protocols, including single chemotherapy agents, multi-drug combination regimens, and high-dose therapy with stem cell rescue, have been tested in both adults and children without clear evidence of benefit [14, 48-55]. Although temozolomide has become part of standard therapy for most adult patients with high-grade gliomas, testing in combination with radiotherapy for newly diagnosed DIPG has demonstrated no improvement in activity compared with radiation alone and is associated with increased risk for side effects and toxicity [38,52,55]. Besides, the incidence of O6-methylguanine-DNA methyltransferase (MGMT) methylation itself was reported to be low in DMG [9]. Clinical trials using other drugs, such as gefitinib, ONC201, and panobinostat, failed to show any clear benefits [56-60].

Nevertheless, temozolomide can be considered first as a chemotherapy regimen in DMG during- and post-radiotherapy (Level II) in the absence of other suitable chemotherapy regi-
men. The reason is that temozolomide has been proven to be an effective and safe drug for the same WHO grade (grade IV) of other brain tumors. In addition, temozolomide acts as a radio-sensitizer when administered together with radiotherapy, thereby enhancing the therapeutic effects of radiation. Therefore, concurrent chemoradiotherapy (± maintenance chemotherapy) can be considered a primary treatment or adjuvant treatment after surgery in DMG (Level II). However, since concurrent chemoradiotherapy may increase treatment-related toxicity, careful decision case by case is needed considering the patient’s condition. If the patient is in old age or in poor condition, temozolomide may be prescribed sequentially after radiotherapy or radiotherapy alone is recommended (Level II). If the disease progresses after radiotherapy, maintenance chemotherapy using temozolomide can be applied (Level III). The single agent or combination therapy of chemotherapeutic agents other than temozolomide can be tried only after full multidisciplinary discussion (Level III). Clinical trials are currently being attempted to prove the effectiveness of other chemotherapeutic agents in DMG, and according to the results, recommendations for chemotherapy may change shortly (Table 4).

**CONCLUSION**

Until now, there has been no practical guideline for the management of adult patients with DMG in Korea. Thus, the KSNO developed this guideline applicable to the current medical circumstances in Korea. “The KSNO Guideline for Adult Diffuse Midline Glioma: Version 2021.01” is the first guideline for H3K27M-mutant diffuse midline glioma in Korea (Fig. 2), prepared by the KSNO Guideline Working Group.

In summary, it is recommended to confirm the presence of H3K27M mutation after the maximal safe resection or biopsy to diagnose the DMG. Radiotherapy is recommended as a primary (or adjuvant) treatment option for tumors incapable of complete resection and concurrent chemotherapy with temozolomide can be considered. However, considering that evidence is still lacking, and treatment-related toxicity may be increased in some patients after concurrent radio-chemotherapy, treatment policy for each patient should be determined through sufficient multidisciplinary discussion.

**Conflicts of Interest**

The authors have no potential conflicts of interest.

**Acknowledgments**

None

**Author Affiliations**

1Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea; 2Department of Radiation Oncology, SMG-SNU Boramae Medical Center, Seoul, Korea; 3Division of
REFERENCES

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2016.

2. Karremann M, Gielen GH, Hoffmann M, et al. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumour location. Neuro Oncol 2018;20:123-31.

3. Schreck KC, Ranjan S, Skorupan N, et al. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol 2019;143:87-93.

4. Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 2012;44:251-3.

5. Nibbañkht H, Panditharatna E, Mikael LG, et al. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat Commun 2016;7:11185.

6. Hoffman LM, DeWire M, Ryall S, et al. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics. Acta Neuropathol Commun 2016;4:1.

7. Louis DN, Giannini C, Capper D, et al. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 2018;135:639-42.

8. Khuong-Quang DA, Buczko P, Rakopoulos P, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 2012;124:439-47.

9. Meyronet D, Esteban-Mader M, Bonnet C, et al. Characteristics of H3 K27M-mutant gliomas in adults. Neuro Oncol 2017;19:1127-34.

10. Walker DA, Liu J, Kieran M, et al. A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro Oncol 2013;15:462-8.

11. Epstein F, Constantini S. Practical decisions in the treatment of pediatric brain stem tumors. Pediatr Neurosurg 1996;24:24-34.

12. Qiu T, Chanchotiawan A, Qin Z, et al. Imaging characteristics of adult H3 K27M-mutant gliomas. J Neurosurg 2020;133:1662-70.

13. Aboian MS, Solomon DA, Felton E, et al. Imaging characteristics of pediatric diffuse midline gliomas with histone H3 K27M mutation. AJNR Am J Neuroradiol 2017;38:795-800.

14. El-Khouly FE, Veldhuizen van Zanten SEM, Santa-Maria Lopez V, et al. Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand? J Neurooncol 2019;145:177-94.

15. Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18:170-86.

16. Sievers P, Sill M, Schimpf D, et al. A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. Neuro Oncol 2021;23:34-43.

17. Weller M, van den Bent M, Tonn JC, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendrogliomas. Lancet Oncol 2017;18: e315-29.

18. Niu X, Wang T, Zhou X, et al. Surgical treatment and survival outcome of patients with adult thalamic glioma: a single institution experience of 8 years. J Neurooncol 2020;147:377-86.

19. Himes BT, Zhang L, Daniels DJ. Treatment strategies in diffuse midline gliomas with the H3K27M mutation: the role of convection-enhanced delivery in overcoming anatomic challenges. Front Oncol 2019;9:31.

20. Cinnalli G, Aguirre DT, Miron G, et al. Surgical treatment of thalamic tumors in children. J Neurosurg Pediatr 2018;21:247-57.

21. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 2006;7:241-8.

22. Kornones DN, Fisher PG, Kretschmar C, et al. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children’s Oncology Group phase II study. Pediatr Blood Cancer 2008;50:227-30.

23. Massimino M, Spreafico F, Biasoni V, et al. Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience. J Neurooncol 2008;87:355-61.

24. Gallitto M, Lazarev S, Wasserman I, et al. Role of radiation therapy in the management of diffuse intrinsic pontine glioma: a systematic review. Adv Radiat Oncol 2019;4:520-31.

25. Combs SE, Steck I, Schulz-Ertner D, et al. Long-term outcome of high-precision radiotherapy in patients with brain stem gliomas: results from a difficult-to-treat patient population using fractionated stereotactic radiotherapy. Radiother Oncol 2009;91:60-6.
26. Muroi A, Minamoto M, Ishikawa E, et al. Proton therapy for newly diagnosed pediatric diffuse intrinsic pontine glioma. Childs Nerv Syst 2020;36:507-12.

27. Mandell LR, Kadota R, Freeman C, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 1999;43:959-64.

28. Freeman CR, Krischer J, Sanford RA, et al. Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: A Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys 1993;27:197-206.

29. Freeman CR, Krischer J, Sanford RA, Burger PC, Cohen M, Norris D. Hyperfractionated radiotherapy in brain stem tumors: results of a Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys 1988;15:311-8.

30. Freeman CR, Krischer J, Sanford RA, et al. Hyperfractionated radiation therapy in brain stem tumors. Results of treatment at the 7020 cGy dose level of Pediatric Oncology Group study #8495. Cancer 1991;68:474-81.

31. Allen J, Siffert J, Donahue B, et al. A phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas. Cancer 1999;86:1064-9.

32. Packer RJ, Boyett JM, Zimmerman RA, et al. Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. A Childrens Cancer Group Phase I/II Trial. Cancer 1993;72:1414-21.

33. Packer RJ, Boyett JM, Zimmerman RA, et al. Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II Trial. Cancer 1994; 74:1827-34.

34. Walter AW, Gajjar A, Ochs JS, et al. Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I/II study. Med Pediatr Oncol 1998;30:28-33.

35. Marcus KJ, Dutton SC, Barnes P, et al. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys 2003;55:1182-5.

36. Zaghloul MS, Eldebawy E, Ahmed S, et al. Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial. Radiother Oncol 2014;111:35-40.

37. Janssens GO, Jansen MH, Lauwers SJ, et al. Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. Int J Radiat Oncol Biol Phys 2013;85:315-20.

38. Izzudddeen Y, Gupta S, Haresh KP, Sharma D, Giridhar P, Rath GK. Hypofractionated radiotherapy with temozolomide in diffuse intrinsic pontine gliomas: a randomized controlled trial. J Neurooncol 2020;146:91-5.

39. Hayashi A, Ito E, Omura M, et al. Hypofractionated radiotherapy in children with diffuse intrinsic pontine glioma. Pediatr Int 2020;62:47-51.

40. Negretti L, Bouchireb K, Levy-Piedbois C, et al. Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution’s experience. J Neurooncol 2011;104:773-7.

41. Zaghloul MS, Akoshis H, Ahmed S, et al. Hypofractionated radiation for pediatric diffuse intrinsic pontine glioma (DIPG): younger children have better survival. Int J Radiat Oncol Biol Phys 2018;101:1008-9.

42. Fontanilla HP, Pinnix CC, Ketten LM, et al. Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol 2012;35:51-7.

43. Lassaleta A, Strother D, Laperriere N, et al. Reirradiation in patients with diffuse intrinsic pontine gliomas: the Canadian experience. Pediatr Blood Cancer 2018;65:e26988.

44. Amsbaugh MJ, Mahajan A, Thall PF, et al. A Phase 1/2 Trial of Reirradiation for Diffuse Intrinsic Pontine Glioma. Int J Radiat Oncol Biol Phys 2019;104:144-8.

45. Janssens GO, Gandola L, Bolle S, et al. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer 2017;73:38-47.

46. Kline C, Liu SJ, Duriseti S, et al. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. J Neurooncol 2018;140:629-38.

47. Massimino M, Biasoni V, Miceli R, et al. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neurooncol 2014;118:305-12.

48. Jennings MT, Sposto R, Boyett JM, et al. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children’s Cancer Group. J Clin Oncol 2002;20:3431-7.

49. Finlay JL, August C, Packer R, et al. High-dose multi-agent chemotherapy followed by bone marrow ‘rescue’ for malignant astrocytomas of childhood and adolescence. J Neurooncol 1990;9:239-48.

50. Bouffet E, Raquin M, Doz F, et al. Radiotherapy followed by high dose busulfan and thiopeta: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer 2000;86:865-92.

51. Dunkel IJ, O’Malley B, Finlay JL. Is there a role for high-dose chemotherapy with stem cell rescue for brain stem tumors of childhood? Pediatr Neurosci 1996;24:263-6.

52. Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group. Neuro Oncol 2011;13:410-6.

53. Jalali R, Raut N, Arora B, et al. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 2010;77:113-8.

54. Sharp JR, Bouffet E, Stempak D, et al. A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. Eur J Cancer 2010;46:3271-9.

55. Bailey S, Howman A, Wheatley K, et al. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy—results of a United Kingdom phase II trial (CNS 2007 04). Eur J Cancer 2013;49:3856-62.

56. Pollack IF, Stewart CF, Kokach M, et al. A phase II study of gefitinib and irinotecan for recurrent or refractory diffuse intrinsic pontine glioma. J Neurooncol 2011;59:1-10.

57. Gilbertson RJ, Hill DA, Hernan R, et al. ERBB1 is amplified and over-expressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res 2003;9(10 Pt 1):3620-4.

58. Chi AS, Tarapore RS, Hall MD, et al. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol 2019;145:97-105.

59. Cooney T, Onar-Thomas A, Huang J, et al. DIPG-22. A phase 1 trial of the histone deacetylase inhibitor panobinostat in pediatric patients with recurrent or refractory diffuse intrinsic pontine glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol 2018;20( Issue suppl_2):i53.

60. Lin GL, Wilson KM, Ceribelli M, et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci Transl Med 2019;11:eaw0064.